Screener
Hemab Therapeutics Holdings, Inc. COAG Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $6,232 | $5,734 |
| Accrued expenses and other current liabilities | 6,252 | 4,296 |
| Operating lease liabilities | 460 | 647 |
| Total current liabilities | 12,944 | 10,677 |
| Operating lease liabilities, net of current portion | 566 | 573 |
| Total liabilities | 13,510 | 11,250 |
| Commitments and contingencies (Note 8) | ||
| Convertible preference shares and convertible preferred stock: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s total current liabilities?
- Hemab Therapeutics Holdings, Inc. (COAG) reported total current liabilities of $12.94M in Q2 2026.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude